OncoMatch/Clinical Trials/NCT07045935
Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment
Is NCT07045935 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Cabergoline (Dopamine Agonist) for prolactinoma.
Treatment: Cabergoline (Dopamine Agonist) — This randomized, active-controlled, parallel-arm, single-blind trial is to compare the effects of Dopamine agonists (DA) therapy targeting different established treatment strategies on glucose metabolism assessed by an oral glucose tolerance test.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Prior therapy
Must have received: dopamine agonist (cabergoline)
Patients treated with cabergoline as DA therapy
Lab requirements
Kidney function
Severe renal impairment (eGFR < 30 ml/min)
Liver function
Severe hepatic insufficiency or cholestasis (Child Pugh C or AST/ALT > 3 x ULN or total bilirubin > 2x ULN)
Severe hepatic insufficiency or cholestasis (Child Pugh C or AST/ ALT > 3 x ULN or Cholestasis (total bilirubin > 2x ULN)); Severe renal impairment (eGFR < 30 ml/min)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07045935 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify